Loading...
XLON
GENF
Market cap4mUSD
Jun 02, Last price  
0.85GBP
1D
0.00%
1Q
-51.43%
IPO
-93.20%
Name

Genflow Biosciences PLC

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
Net income
-2m
L+21.97%
-651,006-988,294-1,335,326-1,628,705
CFO
-2m
L+20.94%
-439,464-747,377-1,368,854-1,655,457

Profile

Genflow Biosciences plc operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing or halting the ageing process, and reducing the incidence of age-related diseases with increase in health span. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. The company was incorporated in 2021 and is headquartered in London, the United Kingdom.
IPO date
Jan 17, 2022
Employees
5
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFY
2023‑122022‑122021‑122021‑03
Income
Revenues
Cost of revenue
1,799
1,390
Unusual Expense (Income)
NOPBT
(1,799)
(1,390)
NOPBT Margin
Operating Taxes
(4)
1
Tax Rate
NOPAT
(1,799)
(1,390)
Net income
(1,629)
21.97%
(1,335)
105.12%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,763
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
84
Net debt
(684)
(2,356)
Cash flow
Cash from operating activities
(1,655)
(1,369)
CAPEX
(2)
(2)
Cash from investing activities
(2)
(2)
Cash from financing activities
3,500
FCF
(2,085)
(1,400)
Balance
Cash
684
2,356
Long term investments
Excess cash
684
2,356
Stockholders' equity
(3,465)
(1,995)
Invested Capital
4,446
4,361
ROIC
ROCE
EV
Common stock shares outstanding
292,507
292,507
Price
Market cap
EV
EBITDA
(1,798)
(1,390)
EV/EBITDA
Interest
382
Interest/NOPBT